MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ALDX had $15,514,162 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$15,514,162
Unit: Dollar
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Stock-based compensation
    • Prepaid expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accrued expenses and other liabi...
    • Net amortization of premium on m...
    • Accounts payable

Cash Flow
2025-12-31
Net loss
-33,846,661
Stock-based compensation
6,091,413
Non-cash interest expense
218,260
Net amortization of premium on marketable securities
1,149,550
Depreciation and amortization expense
251,993
Write-off of deferred offering costs
267,261
Prepaid expenses and other current assets
-1,179,004
Accounts payable
-21,992
Accrued expenses and other liabilities
-6,335,410
Net cash used in operating activities
-33,345,682
Purchases of marketable securities
40,263,712
Maturities of marketable securities
88,000,000
Net cash provided by (used in) investing activities
47,736,288
Issuance costs
0
Proceeds from exercise of stock options
1,103,940
Proceeds from employee stock purchase plan
19,616
Debt end of term charge paid in cash
0
Net cash provided by (used in) financing activities
1,123,556
Net increase (decrease) in cash and cash equivalents
15,514,162
Cash and cash equivalents, beginning of period
54,527,092
Cash and cash equivalents, end of period
70,041,254
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of marketablesecurities$88,000,000 Proceeds from exercise ofstock options$1,103,940 Proceeds from employeestock purchase plan$19,616 Net cash provided by(used in) investing...$47,736,288 Net cash provided by(used in) financing...$1,123,556 Canceled cashflow$40,263,712 Net increase(decrease) in cash and cash...$15,514,162 Canceled cashflow$33,345,682 Purchases of marketablesecurities$40,263,712 Stock-based compensation$6,091,413 Prepaid expenses andother current assets-$1,179,004 Write-off of deferredoffering costs$267,261 Depreciation andamortization expense$251,993 Non-cash interestexpense$218,260 Net cash used inoperating activities-$33,345,682 Canceled cashflow$8,007,931 Net loss-$33,846,661 Accrued expenses andother liabilities-$6,335,410 Net amortization ofpremium on marketable...$1,149,550 Accounts payable-$21,992

Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics, Inc. (ALDX)